AstraZeneca reports mixed clinical results as its rare disease drug Ultomiris failed to achieve statistical significance in a late-stage trial for adult stem cell transplant complications. Despite this setback, which follows other recent pipeline failures in 2026, AstraZeneca's experimental gastric cancer drug sonesitatug vedotin successfully improved overall survival in a Phase III trial. The company still plans pediatric regulatory filings for Ultomiris and targets $80 billion in annual revenue by 2030.
Story comments
Loading comments…